[ET Net News Agency, 2 July 2020] Sino Biopharmaceutical Limited (01177) said
"Clopidogrel Bisulfate Tablet" (brand name: Youliwei), an anticoagulant developed by the
group, has obtained approval for drug registration granted by the National Medical
Products Administration of the People's Republic of China, and is deemed to have passed
the Consistency of Quality and Efficacy Evaluation for Generic Drugs.
The product is applicable to the prevention of atherosclerotic diseases such as
myocardial infarction, ischemic stroke, etc., and has been included in the National
Essential Medicines List.
The approval for launch of this product will further enrich the group's product
portfolio in the cardiocerebrovascular field and consolidate the group's competitive
position in such field. (RC)